Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Watching Bird Flu-Related Stocks Following Report ‘U.S. reports its first human case of H5 bird flu’: BioCryst, NanoViricides, iBio, Inovio
https://www.reuters.com/world/us/us-reports-its-first-human-case-h5-bird-flu-2022-04-29/
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours.
What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings:
Barclays Downgrades BioCryst Pharmaceuticals to Equal-Weight, Lowers Price Target to $13
Barclays analyst Gena Wang downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Overweight to Equal-Weight and lowers the price target from $22 to $13.
